Abstract
BackgroundBreast cancer (BC) is known as the most prevalent type of cancer among women. Trastuzumab, as an anticancer drug, has been used broadly in human epidermal growth factor receptor 2 (HER-2) positive (+) BC patients. Moreover, accumulating evidence has demonstrated that microRNAs is involved in the pathogenesis BC. Hence, we aimed to investigate the effect of trastuzumab on the expression levels of microRNA-26a in HER-2 positive BC patients.MethodsThis study was conducted among HER-2 + and HER-2 Negative (−) BC patients. Serum expression of microRNA-26a was detected by real-time PCR. Then, we assessed the correlations of microRNA-26a levels with multiple clinico-pathological characteristics of BC.ResultsIn HER-2 + patients, the microRNA-26a expression significantly increased after treatment with Docetaxel/Trastuzumab in comparison to before the treatment levels (p.value = 0.01). However, this overexpression in HER-2-patients after treatment with Docetaxel was not significant compared to the levels before the treatment (p.value = 0.14). In addition, the expression of microRNA —26a has significantly increased in HER-2 + patients who were ≤48 years old and premenopausal after the treatment with Docetaxel/Trastuzumab when compared to the levels before the treatment (p.value = 0.039 vs. 0.031, respectively). Furthermore, there was a significant correlation between the expression of microRNA —26a and the tumor size, stage, estrogen receptor (ER) and progesterone receptor (PR) status in the HER-2 + group before and after the treatment (p.value = 0.043, 0.042, 0.049 and 0.034 respectively).ConclusionsTrastuzumab led to overexpression of microRNA-26a in HER-2 + BC patients. It seems that the detecting microRNA —26a expression levels, during or after the trastuzumab therapy could be a useful biomarker for monitoring the therapeutic response in HER-2 + BC patients. However, further studies on large populations of women with HER-2+ BC are needed to explore this possible novel biomarker, in more detail, within various clinical contexts.
Highlights
Breast cancer (BC) is regarded as the most prevalent form of cancer among women in both developed and developing countries, with a high mortality rate worldwide [1]
The present study was conducted among 45 patients with BC, who had been recruited from March 2018 to March 2019, to the Imam Khomeini Hospital in Mazandaran, Iran
A total of 45 (24 HER-2þ and 21 human epidermal growth factor receptor 2 (HER-2)-) patients participated for determining the expression microRNA-26a-5p status before and after Docetaxel therapy in HER-2- group and Docetaxel/Trastuzumab therapy in HER-2þ group
Summary
Breast cancer (BC) is regarded as the most prevalent form of cancer among women in both developed and developing countries, with a high mortality rate worldwide [1]. It was found that approximately 20% of invasive BC cases amplify human epidermal growth factor receptor 2 (HER-2/NEU/c-ERBB2) [2]. HER-2 receptor is a member of the epidermal growth factor receptor (EGFR) family, and its overexpression is associated with proliferation, metastasis, and poor patient's prognosis [3]. Breast cancer (BC) is known as the most prevalent type of cancer among women. Trastuzumab, as an anticancer drug, has been used broadly in human epidermal growth factor receptor 2 (HER-2) positive (þ) BC patients. We aimed to investigate the effect of trastuzumab on the expression levels of microRNA-26a in HER-2 positive BC patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
